基本信息
浏览量:0
职业迁徙
个人简介
She specialised in cellular trafficking and discovered a new protein complex integral to pigmentation: AP-3. “We were the first to describe how eye colour and coat colour in mice were melanosome trafficking mutations,” explains Simpson. “It opened up a new field.” It is now known that human mutations in AP-3 are involved in platelet deficiencies, albinism, melanoma biology, and synaptic vesicle formation in neurons.
Together they developed assays that enabled functional characterisation of novel proteins in endocytosis, the process by which cells internalise substances. She led a collaboration that determined the roles and functional stages of crucial endocytosis proteins, many of which are now known to be essential in neural signalling.
She investigated the translocation mechanism of Glut4, the glucose transporter that responds to insulin, in order to identify ways to overcome insulin resistance in diabetes. As part of this work, she developed a plasma membrane purification method that is now widely used.
“I began working on EGFR immediately,” says Simpson. EGFR is a cell surface receptor known to be integral in regulating numerous cellular functions and is a central molecule in tumourigenesis. In collaboration with oncologists at the Princess Alexandra Hospital (PAH), she demonstrated that both EGFR endocytosis and trafficking within the cell are dysregulated in Squamous Cell Carcinoma (SCC), the most common form of head and neck cancer.
Although anti-EGFR antibodies are used in SCC treatment, patient response varies widely. As such, Simpson’s group has developed an assay that determines whether EGFR trafficking dysregulation correlates with individual treatment responses. She explains that anti-EGFR therapy can have harsh side-effects so it’s important to know who will benefit and who won’t. She aims to develop a prognostic test for anti –EGFR therapy that will guide clinical decisions. “In the longer term,” she adds, “we hope to use our mechanistic information to increase responses to therapy and bypass resistance.”
Access to clinicians, patients, and tumour samples are crucial to Simpson’s work. She explains that the biochemistry of a tumour changes rapidly once removed from the patient, so analysis within half-an-hour of removal is essential. The collaboration between UQDI and PAH enables this.
Simpson believes her findings will have implications for numerous forms of cancer and is passionate about her work. “I have lost family members, including my mother, to cancer. Seeing the patients down in the clinics is also a driver. I love research and find it stimulating, and I enjoy teaching our next generation of research scientists.”
Together they developed assays that enabled functional characterisation of novel proteins in endocytosis, the process by which cells internalise substances. She led a collaboration that determined the roles and functional stages of crucial endocytosis proteins, many of which are now known to be essential in neural signalling.
She investigated the translocation mechanism of Glut4, the glucose transporter that responds to insulin, in order to identify ways to overcome insulin resistance in diabetes. As part of this work, she developed a plasma membrane purification method that is now widely used.
“I began working on EGFR immediately,” says Simpson. EGFR is a cell surface receptor known to be integral in regulating numerous cellular functions and is a central molecule in tumourigenesis. In collaboration with oncologists at the Princess Alexandra Hospital (PAH), she demonstrated that both EGFR endocytosis and trafficking within the cell are dysregulated in Squamous Cell Carcinoma (SCC), the most common form of head and neck cancer.
Although anti-EGFR antibodies are used in SCC treatment, patient response varies widely. As such, Simpson’s group has developed an assay that determines whether EGFR trafficking dysregulation correlates with individual treatment responses. She explains that anti-EGFR therapy can have harsh side-effects so it’s important to know who will benefit and who won’t. She aims to develop a prognostic test for anti –EGFR therapy that will guide clinical decisions. “In the longer term,” she adds, “we hope to use our mechanistic information to increase responses to therapy and bypass resistance.”
Access to clinicians, patients, and tumour samples are crucial to Simpson’s work. She explains that the biochemistry of a tumour changes rapidly once removed from the patient, so analysis within half-an-hour of removal is essential. The collaboration between UQDI and PAH enables this.
Simpson believes her findings will have implications for numerous forms of cancer and is passionate about her work. “I have lost family members, including my mother, to cancer. Seeing the patients down in the clinics is also a driver. I love research and find it stimulating, and I enjoy teaching our next generation of research scientists.”
研究兴趣
论文共 93 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Current Treatment Options in Oncologyno. 3 (2024): 275-283
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2024): 102733-102733
REDOX BIOLOGY (2024): 102976-102976
FRONTIERS IN IMMUNOLOGY (2024): 1336566-1336566
Mehlika Hazar-Rethinam,Lilia Merida de Long,Orla M. Gannon, Samuel Boros,Ana Cristina Vargas,Marcin Dzienis,Pamela Mukhopadhyay,Natalia Saenz-Ponce, Daniel D.E. Dantzic,Fiona Simpson, Nicholas A. Saunders
crossref(2023)
Nature Reviews Cancerno. 7 (2023): 450-473
引用6浏览0WOSNATURE引用
6
0
Molecular pharmaceuticsno. 9 (2023): 4468-4477
CANCER RESEARCHno. 5 (2023)
引用0浏览0引用
0
0
Cancer Researchno. 5_Supplement (2023): OT2-10
引用0浏览0引用
0
0
Peiyu Wang,Renwu Zhou,Rusen Zhou, Shuo Feng,Liqian Zhao,Wenshao Li, Jinyong Lin,Aleksandra Rajapakse,Chia-Hwa Lee,Frank B Furnari, Antony W Burgess,Jennifer H Gunter,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn